Prelude Therapeutics (PRLD) Accounts Payables (2019 - 2026)

Prelude Therapeutics has disclosed Accounts Payables across 8 years of filings, most recently posting $2.1 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $2.1 million, down 64.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.1 million (down 64.52% YoY), and the FY2025 annual result was $4.0 million, down 48.49% from the prior year.
• Accounts Payables came in at $2.1 million for Q1 2026 at Prelude Therapeutics, down from $4.0 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $10.2 million in Q3 2022 to a low of $2.1 million in Q1 2026.
• The 5-year median for Accounts Payables is $5.8 million (2025), against an average of $5.7 million.
• Across the five-year window, Accounts Payables soared 68.82% in 2024 and slumped 64.52% in 2026, its largest moves.
• Prelude Therapeutics' Accounts Payables stood at $6.8 million in 2022, then sank by 32.42% to $4.6 million in 2023, then surged by 68.82% to $7.7 million in 2024, then sank by 48.49% to $4.0 million in 2025, then plunged by 48.05% to $2.1 million in 2026.
• The last three Accounts Payables figures came in at $2.1 million (Q1 2026), $4.0 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.